Prasannan Charulata B, Gmyrek Aleksandra, Martin Tyler A, Villar Maria T, Artigues Antonio, Lee James Ching, Fenton Aron W
Department of Biochemistry and Molecular Biology, The University of Kansas Medical Center, Kansas City, Kansas.
Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, Texas.
Biophys J. 2020 Jun 16;118(12):2966-2978. doi: 10.1016/j.bpj.2020.05.012. Epub 2020 May 20.
The allosteric coupling constant in K-type allosteric systems is defined as a ratio of the binding of substrate in the absence of effector to the binding of the substrate in the presence of a saturating concentration of effector. As a result, the coupling constant is itself an equilibrium value comprised of a ΔH and a TΔS component. In the scenario in which TΔS completely compensates ΔH, no allosteric influence of effector binding on substrate affinity is observed. However, in this "silent coupling" scenario, the presence of effector causes a change in the ΔH associated with substrate binding. A suggestion has now been made that "silent modulators" are ideal drug leads because they can be modified to act as either allosteric activators or inhibitors. Any attempt to rationally design the effector to be an allosteric activator or inhibitor is likely to be benefitted by knowledge of the mechanism that gives rise to coupling. Hydrogen/deuterium exchange with mass spectrometry detection has now been used to identify regions of proteins that experience conformational and/or dynamic changes in the allosteric regulation. Here, we demonstrate the expected temperature dependence of the allosteric regulation of rabbit muscle pyruvate kinase by Ala to demonstrate that this effector reduces substrate (phosphoenolpyruvate) affinity at 35°C and at 10°C but is silent at intermediate temperatures. We then explore the use of hydrogen/deuterium exchange with mass spectrometry to evaluate the areas of the protein that are modified in the mechanism that gives rise to the silent coupling between Ala and phosphoenolpyruvate. Many of the peptide regions of the protein identified as changing in this silent system (Ala as the effector) were included in changes previously identified for allosteric inhibition by Phe.
K型别构系统中的别构偶联常数定义为在没有效应物时底物的结合与在效应物饱和浓度存在时底物的结合之比。因此,偶联常数本身是一个由ΔH和TΔS组分组成的平衡值。在TΔS完全补偿ΔH的情况下,未观察到效应物结合对底物亲和力的别构影响。然而,在这种“沉默偶联”情况下,效应物的存在会导致与底物结合相关的ΔH发生变化。现在有人提出,“沉默调节剂”是理想的药物先导物,因为它们可以被修饰为别构激活剂或抑制剂。任何合理设计效应物成为别构激活剂或抑制剂的尝试都可能受益于对产生偶联机制的了解。现在已经使用氢/氘交换结合质谱检测来鉴定在别构调节中经历构象和/或动态变化的蛋白质区域。在这里,我们通过丙氨酸证明兔肌肉丙酮酸激酶别构调节的预期温度依赖性,以表明该效应物在35°C和10°C时降低底物(磷酸烯醇丙酮酸)亲和力,但在中间温度下是沉默的。然后,我们探索使用氢/氘交换结合质谱来评估蛋白质中在导致丙氨酸和磷酸烯醇丙酮酸之间沉默偶联的机制中发生修饰的区域。在这个沉默系统(丙氨酸作为效应物)中被鉴定为发生变化的蛋白质的许多肽区域都包含在先前鉴定的苯丙氨酸别构抑制所涉及的变化中。